구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Anti-IL23 | Anti-IL12/23 |
Overview Company | Prof. Dr. Stephan Weidinger | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Atopic Dermatitis | Atopic Dermatitis |
Overview Indication | Atopic Dermatitis; Psoriasis | Atopic Dermatitis; Psoriasis |
Overview Phase | PRECLINICAL | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
MoA Mechanism | on multivariate analysis | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic | biomarkers independently predicted survival |
PK/PD Species | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pd |
Toxicology Species | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
Toxicology Animal (cat.) | Mouse | Mouse |
Toxicology Major finding | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Safety signal | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Program phase | PRECLINICAL | PRECLINICAL |
Preclinical Animal (cat.) | Mouse | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Anti-IL23 | Anti-IL12/23 |
Overview Company | Prof. Dr. Stephan Weidinger | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Atopic Dermatitis | Atopic Dermatitis |
Overview Indication | Atopic Dermatitis; Psoriasis | Atopic Dermatitis; Psoriasis |
Overview Phase | PRECLINICAL | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
Overview Content status | Limited Data | Limited Data |
Overview Data Confidence | Data Confidence · Low | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch | Development Signal · Watch |
Overview Approval status | Investigational | Investigational |
MoA Mechanism | on multivariate analysis | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic | biomarkers independently predicted survival |
PK/PD Species | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
PK/PD Animal (cat.) | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pd |
Toxicology Species | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
Toxicology Animal (cat.) | Mouse | Mouse |
Toxicology Major finding | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Safety signal | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Program phase | PRECLINICAL | PRECLINICAL |
Preclinical Animal (cat.) | Mouse | — |
추천 비교
추천 비교